Exhibit 5.1
| | | | |
| | 505 Montgomery Street, Suite 2000 |
| | San Francisco, California 94111-6538 |
| | Tel: +1.415.391.0600 Fax: +1.415.395.8095 |
| | www.lw.com | | |
| |
| | FIRM / AFFILIATE OFFICES |
| Austin | | Milan |
| Beijing | | Moscow |
| | Boston | | Munich |
| | Brussels | | New York |
| | Century City | | Orange County |
October 20, 2021 | | Chicago | | Paris |
| | Dubai | | Riyadh |
| | Düsseldorf | | San Diego |
| | Frankfurt | | San Francisco |
| | Hamburg | | Seoul |
| | Hong Kong | | Shanghai |
| | Houston | | Silicon Valley |
Khosla Ventures Acquisition Co. | | London | | Singapore |
2128 Sand Hill Road | | Los Angeles | | Tokyo |
Menlo Park, California 94025 | | Madrid | | Washington, D.C. |
Re: Registration Statement on Form S-4
Ladies and Gentlemen:
We have acted as special counsel to Khosla Ventures Acquisition Co., a Delaware corporation (the “Company”), in connection with the proposed issuance of (i) 220,691,502 shares of KVSA common stock (the “KVSA Merger Shares”) to be issued in connection with the merger contemplated by that certain Agreement and Plan of Merger, dated as of June 9, 2021, as amended on September 22, 2021 (the “Business Combination Agreement”), by and among the Company, Valo Health, LLC, a Delaware limited liability company (“Valo Holdco”), Valo Health, Inc., a Delaware corporation (“Valo”), and Killington Merger Sub Inc., a Delaware corporation and a direct wholly-owned subsidiary of the Company, and (ii) 15,763,688 shares of KVSA common stock (the “Equity Awards Shares” and, together with the KVSA Merger Shares, the “Shares”) reserved for issuance upon the exercise of options to purchase common stock of Valo outstanding which will convert into options to purchase shares of KVSA common stock in accordance with the terms of the Business Combination Agreement. The Shares are included in a registration statement on Form S-4 under the Securities Act of 1933, as amended (the “Act”), initially filed with the Securities and Exchange Commission (the “Commission”) on July 1, 2021 (Registration No. 333-257591) (as amended, the “Registration Statement”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related proxy statement/prospectus, other than as expressly stated herein with respect to the issue of the Shares.
As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.